Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Tenenbaum, Alexander; Boyko, Valentina; Fisman, Enrique Z; Goldenberg, Ilan; Adler, Yehuda; Feinberg, Micha S; Motro, Michael; Tanne, David; Shemesh, Joseph; Schwammenthal, Ehud; Behar, Solomon
January 2008
Cardiovascular Diabetology;2008, Vol. 7, p1
Academic Journal
Background: Epidemiologic studies have suggested that hypertriglyceridemia and insulin resistance are related to the development of colon cancer. Nuclear peroxisome proliferator-activated receptors (PPAR), which play a central role in lipid and glucose metabolism, had been hypothesized as being involved in colon cancerogenesis. In animal studies the lipid-lowering PPAR ligand bezafibrate suppressed colonic tumors. However, the effect of bezafibrate on colon cancer development in humans is unknown. Therefore, we proposed to investigate a possible preventive effect of bezafibrate on the development of colon cancer in patients with coronary artery disease during a 6-year follow-up. Methods: Our population included 3011 patients without any cancer diagnosis who were enrolled in the randomized, double blind Bezafibrate Infarction Prevention (BIP) Study. The patients received either 400 mg of bezafibrate retard (1506 patients) or placebo (1505 patients) once a day. Cancer incidence data were obtained by matching a subject's identification numbers with the National Cancer Registry. Each matched record was checked for correct identification. Results: Development of new cancer (all types) was recorded in 177 patients: in 79 (5.25%) patients from the bezafibrate group vs. 98 (6.51%) from the placebo group. Development of colon cancer was recorded in 25 patients: in 8 (0.53%) patients from the bezafibrate group vs. 17 (1.13%) from the placebo group, (Fisher's exact test: one side p = 0.05; two side p = 0.07). A difference in the incidence of cancer was only detectable after a 4 year lag and progressively increased with continued followup. On multivariable analysis the colon cancer risk in patients who received bezafibrate tended to be lower with a hazard ratio of 0.47 and 95% confidence interval 0.2-1.1. Conclusion: Our data, derived from patients with coronary artery disease, support the hypothesis regarding a possible preventive effect of bezafibrate on the development of colon cancer.


Related Articles

  • Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia. Koh, Kwang Kon; Han, Seung Hwan; Quon, Michael J.; Ahn, Jeong Yeal; Shin, Eak Kyun // Diabetes Care;Jun2005, Vol. 28 Issue 6, p1419 

    OBJECTIVE -- Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary, heart disease. We hypothesize fenofibrate improves endothelial function by enhancing insulin sensitivity. RESEARCH...

  • Effect of Type 1 Diabetes on the Gender Difference in Coronary Artery Calcification: a Role for Insulin Resistance? Dabelea, Dana; Kinney, Gregory; Snell-Bergeon, Janet K.; Hokanson, John E.; Hamman, Richard F.; Eckel, Robert H.; Ehrlich, James; Garg, Satish; Rewers, Marian // Diabetes;Nov2003, Vol. 52 Issue 11, p2833 

    The objective of this is study was to examine whether estimated insulin resistance and insulin resistancerelated factors are associated with coronary artery calcification (CAC) in 1,420 asymptomatic participants in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. A total of...

  • Combination fecal testing is most effective strategy for finding cancers.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p51 

    Presents the abstract of the study entitled `A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening,' by Allison, Tekawa et al published in the January 18, 1996 issue of the `New England Journal of Medicine' periodical concerning the diagnosis of colonic cancers.

  • Screen for colorectal cancer once a year. Begany, Timothy // RN;Dec93, Vol. 56 Issue 12, p17 

    Reports on the lower mortality rate of men and women tested annually for colorectal cancer by fecal occult-blood testing. `New England Journal of Medicine' as source; Mortality for those screened every two years; Discovery and treatment at an earlier age.

  • What to do now to screen for colorectal cancer. Glaser, Vicki; Early, Dayna S.; Fletcher, Robert; Rodney, W.M. MacMillan // Patient Care;6/15/1998, Vol. 32 Issue 11, p206 

    Focuses on issues pertaining to screening for colorectal cancer. Characteristics of colorectal cancer which make it an excellent target for systematic screening; Information on the American Cancer Society (ACS) guidelines regarding screening for colorectal cancer; When should screening for...

  • Gene Screen for Early Colon Cancer. J.M. // Prevention;Jul2002, Vol. 54 Issue 7, p159 

    Reports on a test called Digital Protein Truncation to detect early-colon cancer.

  • New diagnostic criteria for HNPCC are on the way. Kuska, Bob // JNCI: Journal of the National Cancer Institute;01/01/97, Vol. 89 Issue 1, p11 

    Reports on a diagnostic Bethesda criteria for hereditary non-polyposis colon cancer (HNPCC). Similarity with a sporadic colon tumor; Genetically oriented criteria for the diagnosis of HNPCC; Testing for mutations in the HNPCC genes.

  • Screening cancer.  // Joe Weider's Muscle & Fitness;Mar94, Vol. 55 Issue 3, p26 

    Reports on the diagnosis of colorectal cancer at a curable stage. Recommendation for people over age 50 for yearly test.

  • Colon check.  // Joe Weider's Muscle & Fitness;Feb96, Vol. 57 Issue 2, p28 

    Talks about the importance of having a colon cancer check-up. Reason for putting-off colon checkups; Mechanics of the method called virtual colonoscopy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics